Roche Calls Illumina Offer 'Full and Fair'

February 5, 2012

February 6, 2012 | Roche's $44.50/share offering for Illumina is "a full and fair price," Roche CEO Severin Schwan told CNBC. He said the pharma company is "committed to making [the] transaction happen." CNBC